Monocyten hun verdiende erkenning geven: CD47-SIRPα herkadert allograaftstoting

Despite decades of therapeutic innovation targeting adaptive immunity, such as the development of calcineurin inhibitors and B-cell–depleting agents, like rituximab, long-term graft survival rates have stagnated, with nearly half of allografts failing within 10 years. This enduring challenge underscores a critical oversight in transplant immunology: the predominant focus on adaptive immune responses has largely neglected the role of innate immunity in graft rejection. Historically, rejection was attributed to T- and B-cell recognition of donor major histocompatibility complex (human leukocyte antigen [HLA]) molecules, relegating innate immune cells to a secondary role.